Ceftriaxone: Clinical Guidelines and Recommendations

I. Introduction to Ceftriaxone

• The American Academy of Otolaryngology-Head and Neck Surgery recommends ceftriaxone for the treatment of respiratory pathogens, including Haemophilus influenzae, Haemophilus parainfluenzae, and Moraxella catarrhalis 2
• The Infectious Diseases Society of America recommends ceftriaxone for the treatment of meningitis caused by Streptococcus pneumoniae, with a dosing regimen of 2 g IV every 12 hours 3

II. Antimicrobial Spectrum and Resistance

• Ceftriaxone has excellent activity against most clinically significant Gram-negative aerobic bacilli, including Enterobacteriaceae, Haemophilus influenzae, and Neisseria species 2
• The European Society of Clinical Microbiology and Infectious Diseases notes that ceftriaxone has no activity against methicillin-resistant Staphylococcus aureus (MRSA) 4, 5
• Ceftriaxone is not recommended as sole therapy for Pseudomonas aeruginosa infections due to limited activity 4, 5

III. Clinical Indications and Dosing Regimens

• The Centers for Disease Control and Prevention recommend a single 125 mg IM dose of ceftriaxone for the treatment of uncomplicated gonorrhea, including penicillinase-producing strains 8
• For meningitis, the recommended dosing regimen is 50 mg/kg (maximum 1 g) IM or IV once daily for 7 days, with an increased duration of 10-14 days and maximum dose of 2 g for meningitis 8
• The American Diabetes Association recommends ceftriaxone for the treatment of moderate to severe diabetic foot infections, with a dosing regimen of 1-2 g IV/IM once daily 9, 10

IV. Pharmacokinetics and Pharmacodynamics

• Ceftriaxone has a long elimination half-life of 5.8-8.7 hours, enabling once-daily dosing 2, 6, 7
• The American Academy of Otolaryngology-Head and Neck Surgery notes that ceftriaxone requires a free AUIC (area under the inhibitory curve) of at least 125 for optimal efficacy 2